Why the study?
Does chlorpromazine affect serum cholesterol levels and cholesterol-behavior relationships in women with chronic schizophrenia?
Does chlorpromazine affect serum cholesterol levels and cholesterol-behavior relationships in women with chronic schizophrenia?
Chlorpromazine therapy in women with chronic schizophrenia significantly increases serum cholesterol levels and alters the relationship between cholesterol and behavioral symptoms.
Answers are grounded in this paper and cite their sources.
May warrant lipid monitoring in chlorpromazine-treated schizophrenia; hypothesis-generating for cholesterol-psychopathology links and requires prospective confirmation.
In 2 carefully controlled studies with the same women with chronic schizophrenia, chlorpromazine was shown to raise serum cholesterol levels consistently and significantly. It was also a consistent finding that prior to chlorpromazine therapy cholesterol levels appeared to be related inversely to measures of withdrawal, seclusiveness, and gross psychopathology. After chlorpromazine therapy the cholesterol-behavior relationships were no longer apparent.
No takes yet. Share an insight, caveat, or question.
Clark et al. (1967) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: